F-Fluoroestradiol: Current Applications and Future Directions.

Sophia R O'Brien, Christine E Edmonds, Shannon M Lanzo, Joanna K Weeks, David A Mankoff, Austin R Pantel

March 2023 Radiographics

Synopsis of Social media discussions

Overall, the discussions are enthusiastic and highlight the clinical importance of FES PET/CT, with language emphasizing excitement and future potential, such as 'so excited' and 'current applications and future directions.' References to using FES in metastatic breast cancer convey both interest and perceived value, indicating a positive outlook on the research's role in advancing targeted diagnostics.

A
Agreement
 Moderate agreement

Most discussions support the article and recognize the value of FES PET/CT in evaluating ER in breast cancer, indicating general agreement with its significance.

I
Interest
 High level of interest

The enthusiasm expressed, such as 'SO excited' and highlighting the article’s clinical applications, demonstrates high interest.

E
Engagement
 Moderate level of engagement

Posts reference specific techniques like FES PET/CT and mention collaborative efforts, showing moderate engagement with technical and team aspects.

I
Impact
 Moderate level of impact

The attention to clinical relevance and advancements in personalized medicine suggests a positive view of the publication’s impact.

Social Mentions

YouTube

2 Videos

Twitter

14 Posts

Metrics

Video Views

186

Total Likes

53

Extended Reach

59,060

Social Features

16

Timeline: Posts about article

Top Social Media Posts

Posts referencing the article

FES PET-CT in Breast Cancer Diagnosis and Management

FES PET-CT in Breast Cancer Diagnosis and Management

Drs Sophia OBrien Austin Pantel explore the role of 18FFluoroestradiol FES PETCT in diagnosing and managing ER-positive breast cancer. FES imaging enhances patient care by assessing estrogen receptor expression across all disease sites, supporting precision medicine.

RadioGraphics

August 31, 2025

99 views

Fluoroestradiol PET Imaging: Current Uses and Future Prospects

Fluoroestradiol PET Imaging: Current Uses and Future Prospects

Guest host Dr. Matt Covington summarizes the article on Fluoroestradiol's current applications and future directions. Fluoroestradiol PET imaging helps evaluate estrogen receptor expression in breast cancer, enabling personalized treatment decisions and assessing tumor heterogeneity.

RadioGraphics

April 4, 2024

87 views

  • Randy C. Miles MD, MPH, FSBI
    @RMilesMD (Twitter)

    #18FFluoroestradiol: Current Applications and Future Directions Sophia R. O’Brien, MD et al. @PennMedicine https://t.co/7YwljCDOJ7 @RadioGraphics #BreastCancer #MBC #ERPositiveBreastCa https://t.co/PR0uOuDI6y
    view full post

    April 4, 2023

  • drnowhere
    @drnowhere00 (Twitter)

    RT @RadioGraphics: Fluorine 18 fluoroestradiol is an FDA-approved radiotracer that allows noninvasive evaluation of estrogen receptor expre…
    view full post

    March 29, 2023

    11

  • Dr Alok Dixit
    @Alokdoctor (Twitter)

    RT @RadioGraphics: Fluorine 18 fluoroestradiol is an FDA-approved radiotracer that allows noninvasive evaluation of estrogen receptor expre…
    view full post

    March 29, 2023

    11

  • Sara Hunter, MD
    @SaraHunterMD (Twitter)

    RT @RadioGraphics: Fluorine 18 fluoroestradiol is an FDA-approved radiotracer that allows noninvasive evaluation of estrogen receptor expre…
    view full post

    March 29, 2023

    11

  • Julian G. Rojas
    @julired3 (Twitter)

    RT @RadioGraphics: Fluorine 18 fluoroestradiol is an FDA-approved radiotracer that allows noninvasive evaluation of estrogen receptor expre…
    view full post

    March 29, 2023

    11

  • Jonathan Revels DO, FNASCI, FSAR
    @JRevRad1 (Twitter)

    RT @RadioGraphics: Fluorine 18 fluoroestradiol is an FDA-approved radiotracer that allows noninvasive evaluation of estrogen receptor expre…
    view full post

    March 29, 2023

    11

  • Envy
    @Envywithnyang (Twitter)

    RT @RadioGraphics: Fluorine 18 fluoroestradiol is an FDA-approved radiotracer that allows noninvasive evaluation of estrogen receptor expre…
    view full post

    March 29, 2023

    11

  • RadioGraphics
    @RadioGraphics (Twitter)

    Fluorine 18 fluoroestradiol is an FDA-approved radiotracer that allows noninvasive evaluation of estrogen receptor expression at PET in women with recurrent or metastatic breast cancer and is an excellent adjunct to biopsy. @SophiaObrien_ @DrCEdmonds https://t.co/eHOpLJIghE https://t.co/cScfyeSKJb
    view full post

    March 29, 2023

    24

    11


  • @atomhightech (Twitter)

    RT @SophiaObrien__: I am SO excited to share our Radiographics article on FES PET/CT (currently used in pts with metastatic/recurrent ER+ b…
    view full post

    March 4, 2023

    2

  • Charmi Vijapura, MD, MEd
    @CharmiMD (Twitter)

    RT @RadG_Editor: 18F-Fluoroestradiol (18F FES): Current Applications and Future Directions O’Brien SR et al Nuclear Medicine https://t.co/c…
    view full post

    March 3, 2023

    2

  • Jamie Clarke, MD, MS
    @JamieClarkeRad (Twitter)

    RT @RadG_Editor: 18F-Fluoroestradiol (18F FES): Current Applications and Future Directions O’Brien SR et al Nuclear Medicine https://t.co/c…
    view full post

    March 3, 2023

    2

  • RadioGraphics_Editor
    @RadG_Editor (Twitter)

    18F-Fluoroestradiol (18F FES): Current Applications and Future Directions O’Brien SR et al Nuclear Medicine https://t.co/crHTeHEkXB @SophiaObrien_ @DrCEdmonds @PennRadiology #RGphx 9/12 https://t.co/K1U2GEfoLs
    view full post

    March 3, 2023

    7

    2

  • Penn Radiology Residents
    @PennRadRes (Twitter)

    RT @SophiaObrien__: I am SO excited to share our Radiographics article on FES PET/CT (currently used in pts with metastatic/recurrent ER+ b…
    view full post

    March 3, 2023

    2

  • Sophie O’Brien
    @SophiaObrien__ (Twitter)

    I am SO excited to share our Radiographics article on FES PET/CT (currently used in pts with metastatic/recurrent ER+ breast cancer): https://t.co/0vjmbYMMrC. And honored to work with an amazing team of colleagues and mentors on this project including @DrCEdmonds
    view full post

    March 1, 2023

    22

    2

Abstract Synopsis

  • Fluoroestradiol (FES) is a PET radiotracer approved in the US in 2020 to help evaluate estrogen receptor (ER) expression in breast cancer patients, especially those with ER-positive metastatic or recurrent disease.
  • FES binds to ER in the nuclei of tumor cells, allowing for whole-body, in vivo assessment of ER status, overcoming limitations of traditional biopsy methods like sampling error and inability to assess all metastatic sites.
  • This application of FES exemplifies precision medicine by enabling tailored treatment decisions and better understanding of ER heterogeneity over time and across different tumor sites.]